MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors

• Published in: Hematology/oncology clinics of North America Vol. 9; no. 2; p. 319
• Main Authors: Lum, B L, Gosland, M P
• Format: Journal Article
• Language: English
• Published: United States 01.04.1995
• Subjects: Adrenal Cortex - metabolism; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors; ATP-Binding Cassette, Sub-Family B, Member 1 - biosynthesis; ATP-Binding Cassette, Sub-Family B, Member 1 - genetics; ATP-Binding Cassette, Sub-Family B, Member 1 - physiology; Biological Transport - drug effects; Blood-Brain Barrier; Blood-Testis Barrier; Calcium Channel Blockers - pharmacology; Cyclosporins - pharmacology; Digestive System - metabolism; Gene Expression Regulation; Kidney - metabolism; Reference Values; Steroids - metabolism

The use of drugs such as calcium channel blocker agents and cyclosporins as an approach to reverse the MDR phenomenon in controlled clinical trials has demonstrated the combination of these agents to markedly alter the pharmacokinetics of a number of cytotoxins associated with MDR characteristics, i...